Gut microbiome and health: mechanistic insights

Willem M de Vos 1,2, Herbert Tilg 3, Matthias Van Hul 4, Patrice D Cani 4

ABSTRACT
The gut microbiota is now considered as one of the key elements contributing to the regulation of host health. Virtually all our body sites are colonised by microbes suggesting different types of crosstalk with our organs. Because of the development of molecular tools and techniques (ie, metagenomic, metabolomic, lipidomic, metatranscriptomic), the complex interactions occurring between the host and the different microorganisms are progressively being deciphered. Nowadays, gut microbiota deviations are linked with many diseases including obesity, type 2 diabetes, hepatic steatosis, intestinal bowel diseases (IBDs) and several types of cancer. Thus, suggesting that various pathways involved in immunity, energy, lipid and glucose metabolism are affected.

In this review, specific attention is given to provide a critical evaluation of the current understanding in this field. Numerous molecular mechanisms explaining how gut bacteria might be causally linked with the protection or the onset of diseases are discussed. We examine well-established metabolites (ie, short-chain fatty acids, bile acids, trimethylamine N-oxide) and extend this to more recently identified molecular actors (ie, endocannabinoids, bioactive lipids, phenolic-derived compounds, advanced glycation end products and enteroyxins) and their specific receptors such as peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARY), aryl hydrocarbon receptor (AhR), and G protein-coupled receptors (ie, GPR41, GPR43, GPR119, Takeda G protein-coupled receptor 5).

Altogether, understanding the complexity and the molecular aspects linking gut microbes to health will help to set the basis for novel therapies that are already being developed.

THE HUMAN GUT MICROBIOME
The human microbiome is considered here as the collection of microbes, their genes and their products that colonise our body since birth and are transferred vertically. While all body sites are colonised (figure 1), the highest microbial numbers are found in the gut that has been studied extensively. Here, we review the main and most recent findings that address the way gut microbes, their activities and mediator molecules can contribute to our health.

In healthy subjects, the oral and saliva microbiomes contain millions of microbes that are swallowed daily with our food, but their persistence in the gut is impeded by many factors, including the acidity of the stomach, the production of bile acids (BAs), digestive enzymes and antimicrobial proteins in the duodenum and beyond. A great number of other major variables affect further downstream microbial colonisation, such as chemical parameters like pH, oxygen concentrations and redox potential, the biological production of mucus, bile and antibodies, as well as physical aspects, including gut architecture, peristalsis and transit times (figure 1). Hence, a concentration gradient of microbes is found along the small intestine, as microbial abundance in duodenal aspirates were found to be a 1000-fold lower than that of oral samples, although consisting of somewhat similar microbial taxa. Consequently, the small intestine contains an increasing number of thousands to several hundred million of cells per gram of content with partly oxygen-tolerant Firmicutes and Proteobacteria as major phyla.

This all culminates in the lower gut where climax communities of up to 100 billion cells per gram reside for up to a few days, since transit in the colon is over a dozen times longer than that in the small intestine. Hence, the colonic microbiome is dominated by mainly anaerobic bacteria, including thousands of species and millions of genes, distributed among the major phyla of Firmicutes (predominantly Ruminococcaceae and Lachnospiraceae), Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia (Akkermansia) (1,10) (figure 1). Excreted as faeces, this is the biomass that makes up what is usually termed the gut microbiome that has been associated with a plethora of diseases and is highly modifiable by diet and drugs (table 1). It provides the starting material for faecal microbiota transplantation (FMT) that has been shown to cure patients with recurrent Clostridioides difficile infections and other diseases.

It is important to note that we can live without a colon but not without a small intestine that features the largest mucosal surfaces of our body where our food is further digested and taken up, contains most of the gut receptors, immune and nerve cells and is increasingly implied in essential microbe-host crosstalk. While hard to approach experimentally, a variety of new technologies have been developed in recent years, which include catheters or capsules to sample, deliver or inspect. In addition, small intestinal effluent obtained from ileostomies was studied and found to contain up to 100 million microbes per gram wet weight that formed personalised communities, showing day and night rhythms reflecting food intake and processing. Functional (transcriptomics and targeted metabolomics) and metagenomic analysis of such samples revealed the colonising Streptococcus and Lactobacillus spp to express a large reservoir of highly effective transport systems that compete with the host for sugar uptake and use, generating lactate and acetate that are substrates for Veillonella spp and are converted then into propionate. Recent studies using specially developed catheters confirmed these
communities and revealed that the duodenal microbiota exhibited higher compositional dynamics correlating with the pH as compared with the jejunum, which is the intestinal compartment with the largest surface and is responsible for most sugar, protein and lipid digestion and absorption.\(^5\)\(^2\) While there is a continuum between the duodenum and jejunum, the more proximal ileum has a large mucus layer, reminiscent of the colon, and is colonised with several anaerobes, including members of the Bacteroidia, Ruminococcaceae and Lachnospiraceae, some of which are also implied in BAs transformation (see section bioactive lipids/bile acids).\(^2\)\(^1\)\(^2\)

The duodenum and its microbes have emerged as a major factor in a variety of metabolic and possibly immune diseases.\(^2\)\(^1\) Support for this and further new insight derived from duodenal delivery of FMT that alleviated symptoms of metabolic syndrome or autoimmune disease.\(^2\)\(^4\)\^-\(^2\)\(^6\) Moreover, duodenal perfusions of live or dead Lactobacillus spp have been found to affect the host immune response, providing an experimental system for human discovery.\(^2\)\(^7\)\^-\(^2\)\(^9\) This has been recently exploited for the analysis of a single duodenal dose of Anaerobutyricum soehngenii (previously known as Eubacterium hallii)\(^3\)\(^0\) that increased the duodenal expression level of the gene for regenerating islet-protein 1B almost 10-fold and also increased serum glucagon-like peptide-1 (GLP-1) and secondary bile salts in metabolic syndrome subjects, thereby potentially explaining their improved response to glucose.\(^3\)\(^1\)\(^\)\(^2\)

Although there is an evident vertical gradient in the gut, a horizontal gradient also exists and has been studied most extensively in the colon. Importantly, there exist oxygen, redox and mucus gradients that starts at the mucosal surface and stretches to the lumen, resulting in architecture of the microbial communities.\(^3\)\(^3\) Broadly speaking, these start with mucus-degrading consortia that are usually dominated by the mucolytic and microaerophilic Akkermansia muciniphila and end with strictly anaerobic communities, including butyrate-producing and propionate-producing Ruminococcaceae, Lachnospiraceae and Bacteroidia as well as homoacetogens and methanogens that convert hydrogen and carbon dioxide into acetate or methane, respectively.

---

**Figure 1** Total abundance of bacteria according to the different body sites. Bounds for bacteria number in different organs, derived from bacterial concentrations and volume.\(^1\)\(^9\)\(^0\)\^-\(^1\)\(^9\)

| Diseases                          | PubMed search | PubMed search |
|----------------------------------|---------------|---------------|
|                                  | "disease & microbiome" | "disease & microbiome/clinical trial" |
| IBDs                             | 2867          | 36            |
| Coeliac disease                  | 524           | 20            |
| IBS                              | 1516          | 96            |
| Colorectal carcinoma             | 1525          | 43            |
| Liver disease                    | 4927          | 113           |
| Pancreatic disease               | 766           | 20            |
| Obesity                          | 7146          | 292           |
| Type 2 diabetes                  | 2155          | 99            |
| Non-alcoholic fatty liver disease | 1383          | 31            |

PubMed search 15 December 2021.
THE GUT MICROBIOME AND VARIOUS INTESTINAL AND EXTRAINTESTINAL DISEASES

The gut microbiome has been associated with several intestinal and extraintestinal disorders. Many large studies investigating the gut microbiome and its relevance have been performed in specific gastrointestinal (GI) disorders such as intestinal bowel diseases (IBDs), coeliac disease, irritable bowel syndrome (IBS), colorectal cancer (CRC), chronic liver diseases, or pancreatic disorders. IBDs, prototypic inflammatory disorders of the intestine, are associated with deviating gut microbiome composition and indeed facultative anaerobes outgrow have been reported, especially in the context of active inflammation and metabolite disturbances including BAs, short chain fatty acids (SCFAs) and acylcarnitine pathways. Longitudinal analysis in infants at risk for coeliac disease, another frequent inflammatory intestinal disorder, demonstrated an increased presence of several microbial species such as Dialister invisus, Parabacteroides spp or Lachnospiraceae and certain metabolites such as tryptophan metabolites before disease onset whereas various anti-inflammatory strains such as Faecalibacterium prausnitzii or Clostridium clostridioforme were decreased. IBS, a frequent functional disorder of the GI tract, has been associated with IBS subtype-specific changes in the gut microbiome and related metabolites, with purine metabolism being especially affected. CRC, the most common malignancy in the lower gut, has been convincingly correlated with a disturbed gut microbiome and implicated certain bacteria such as Fusobacterium nucleatum, Escherichia coli or Bacteroides fragilis, some of which are derived from the oral microbiome. Chronic liver diseases, especially advanced liver diseases such as liver cirrhosis, are characterised by profound microbial aberrations and data from interventional studies with prebiotics, probiotics and antibiotics have well established that the gut microbiome plays a key role in these diseases. Pancreatic adenocarcinoma, an increasingly recognised malignancy in the Western world, has also been linked to an impaired gut microbiome as intratumoral microbiome composition affects the host immune response and natural history of the disease.

The gut microbiome has been extensively investigated in the past years in obesity and obesity-related disorders such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Many studies have tried to link an altered gut microbiome to obesity and indeed interventional studies with certain bacterial strains such as Akkermansia muciniphila have shown effects on obesity-related parameters. T2D has also been characterised by an impaired gut microbiome in Asian and European populations. In T2D, microbial variations were strongly correlated to metabolic parameters. Several studies have now demonstrated that NAFLD is characterised by a bloom in certain Enterobacteriaceae, E. coli and a decrease in F. prausnitzii. Recent data also suggest that in NAFLD microbiome deviations and instability may exist over many years and might even precede development of NAFLD and T2D. There is a growing number of GI and metabolic disorders where the gut microbiome has been investigated (see table 1 for an overview).

Figure 2 Molecules and metabolites produced by the gut microbiota according to the nutrients or metabolic source and their derived compounds. BSCFA, branched SCFA; LPS, lipopolysaccharides; PAMPs, pathogen-associated molecular patterns; SCFA, short chain fatty acids.

GUT MICROBES AND METABOLIC DISORDERS: MOLECULAR ACTORS

The gut bacterial community plays an important role in the regulation of multiple aspects of metabolic disorders. This regulation depends, among other things, on the production of a wide variety of metabolites by the microbiota and on their interactions with receptors on host cells that can activate or inhibit signalling pathways, and either be beneficial and detrimental to the host’s health (figure 2).

The bacterial metabolites involved in these interactions are very diverse and range from small molecules to large macromolecules. They include by-products of bacterial metabolism, such as SCFAs, and complex macromolecules necessary for bacterial integrity, such as peptidoglycan and lipopolysaccharides (LPS) (figure 2).

The abundance and availability of these metabolites are dependent on the microbial composition and are therefore subject to modulation by diet and environmental factors. The main molecular actors are discussed below.

Short chain fatty acids and impact on host health: molecular mechanisms

The small intestine is highly specialised in the breakdown, emulsification and absorption of nutrients and few nutrients will escape digestion. In normal conditions, for example, <5 g/day of fat will reach the colon. The same principle is true for the digestion and absorption of simple carbohydrates (broken down into sugar molecules) and most proteins (converted into amino acids), although, depending on the level of intake, some proteins will reach the colon. Conversely, complex carbohydrates, such as dietary fibres are non-digestible, meaning that the body lacks the necessary enzymes to digest them allowing them to escape digestion in the small intestine. In the colon, however, they can be used as an energy source by specific resident bacteria. Various gut microbes will contribute to the metabolism of these non-digestible carbohydrates into different SCFAs molecules (eg,
Nowadays, these microbial metabolites are known to contribute to liver, the adipose tissue, the muscles and the brain (figure 3). Molecular mechanisms linking gut microbiota and host health in both healthy and pathological situation. In healthy situation, colonocytes use butyrate as energy substrate via the beta-oxidation in the mitochondria, thereby consuming oxygen and directly contributing to maintain anaerobic condition in the lumen. Butyrate also binds to peroxisome proliferator-activated receptor gamma (PPARγ) which in turn repress inducible nitric oxide synthase (iNOS), decreases nitric oxide production (NO) and eventually nitrate production. Conversely, in pathological situations low butyrate content in the lumen is associated with lower PPARγ activity, increased glycolysis and lower oxygen consumption. This is associated with a higher expression of iNOS which in turn produces more NO and eventually increases nitrates availability for specific pathogens. Butyrate can also stimulate immune cells such as regulatory T cells (Treg) to reduce inflammation. The nuclear transcription factor aryl hydrocarbon receptor (AhR) is highly expressed in healthy colonocytes, whereas agonists of AhR are low or reduced AhR activity can lead to altered gut barrier function. Enteromedullary cells (L-cells) are expressing several key receptors activated by short chain fatty acids (SCFAs), specific endocannabinoids (eCBs) and bile acids (BAs). Activating these receptors increase the secretion of key gut peptides such as glucagon-like peptide (GLP)-1, GLP-2 and peptide YY (PYY). Altogether, the interaction between the gut microbes and these molecular actors contributes to reduce intestinal permeability, to improve insulin secretion and insulin sensitivity, to reduce food intake, to lower plasma lipids and to avoid hepatic steatosis and metabolic endotoxaemia. All these effects are associated with lower inflammation. Conversely, opposite effects have been observed in pathological situations.

SCFAs stimulate the secretion of gut peptides by acting on specific G-protein-coupled receptors expressed at the surface of the enteromedullary L-cells that are specifically abundant in the terminal ileum and colon. These receptors, named G-protein-coupled receptor (GPR)43 (or free fatty acid receptor 2 (FFAR2)) and GPR41 (or FFAR3) (figure 3), are also expressed in a wide variety of tissues and cell types (eg, adipocytes, immune cells). The key role played by the microbiome on the secretion of the gut peptides has been elucidated using mouse models lacking either GPR43 or GPR41. Mice lacking these receptors exhibit reduced secretion of GLP-1 and PYY after exposure to SCFAs or specific prebiotics (figure 3).

In addition to their well-known role and mechanisms of action, some SCFAs might also exert different functions from what has previously been thought. For example, butyrate has been described many times as an essential energy source for the colonic cells to proliferate and maintain the gut barrier. However, recent evidence shows that butyrate also strongly influences the microbial environment by communicating with colonic cells. Indeed, the abundance of oxygen in the luminal part of the gut and its gradually decreasing concentration towards the epithelium is a key requirement for anaerobic bacteria to remain in the close vicinity of the epithelium as opposed to facultative anaerobes such as Enterobacteriaceae (phylum Proteobacteria) that have been shown to increase the risk of intestinal inflammation (figure 3). Butyrate contributes to control of the anaerobic condition in the colon by activating the β-oxidation in the mitochondria. By activating the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) in the colonic cells, butyrate limits the diffusion of oxygen from the colonocytes to the luminal part, thereby maintaining the anaerobic conditions. The activation of PPARγ also represses the expression of the gene encoding inducible nitric oxide synthase, thereby reducing NO production and ultimately luminal nitrate levels that are specific energy sources used for the proliferation of putative pathogenic facultative anaerobes (Enterobacteriaceae) (figure 3).
besides propionate and butyrate, the impact of succinate is also being investigated. succinate is best known as an intermediate of the Krebs cycle and considered as a substrate for mitochondrial oxidative phosphorylation, but is also a metabolic product from bacteria. in this context, succinate has been classically ignored because it was considered as being mainly a key intermediate in propionate synthesis. Currently, the role of succinate remains largely a matter of debate as there have been reports of both beneficial and opposite associations between succinate and insulin resistance, obesity and inflammation.

**Lipopolysaccharides/pathogen-associated molecular patterns**

The gut barrier is a complex and dynamic collection of physical and chemical structures that surveil the environment and protects the host from microbial invaders and harmful stimuli. Some of these hazardous components coming from the environment are the so-called pathogen-associated molecular patterns (PAMPs), of which bacterial LPS are the prototypical class.

LPS, endotoxins found on the cell membranes of Gram-negative bacteria, are potent activators of the inflammatory response and release of even small amounts of LPS into the circulation are sufficient to elicit an inflammatory response.

LPS and other PAMPs exert their activity through activation of specific pattern recognition receptors (PRRs) that sense microorganisms and infectious agents and signal a defensive response. There are four major subfamilies of PRRs: the toll-like receptors (TLRs), the nucleotide-binding oligomerisation domain-leucine-rich repeats (LRR)-containing receptors, the retinoic acid-inducible gene 1 (RIG-1)-like receptors (aka RIG-1-like helicases) and the C-type lectin receptors. Among those the TLRs, a family of receptors comprising 10 members in human (13 in mice), are the best characterised. Each of the TLRs mediates responses to distinct microbial components derived from pathogens. Two typical examples are TLR2, which senses bacterial lipoproteins, and TLR4, which recognises bacterial LPS.

Together the TLRs cover a wide range of both external stimuli (PAMPs) and internal signals derived from tissue damage (damage-associated molecular patterns (DAMPs)) (figures 3 and 4). These ligands come in many forms and sizes: from nucleic acids to lipids, from small compounds to macromolecules. TLRs are widely distributed in immune cells including macrophages, neutrophils, dendritic cells, natural killer cells, mast cells, basophils and eosinophils, but also in other body cells, such as intestinal epithelial cells. Their activation induces antigen-presenting cell activation, thereby bridging the innate and the adaptive immune responses, and stimulates signalling cascades as an attempt to fend off microbial invaders or repair the damaged tissue. Although this inflammatory response is required to eliminate the infection, excessive activation of TLRs can lead to disruption of immune homeostasis and the sustained pro-inflammatory cytokines and chemokine production can increase the risk of inflammatory diseases and autoimmune disorders.

This is the case in metabolic endotoxaemia, in which high-fat diet and weight gain have been associated with a higher gut permeability and subsequent systemic (mild) elevation in circulating plasma LPS. This causes a state of low-grade inflammation, which is a pathological feature of a range of chronic conditions including T2D, NAFLD, chronic kidney disease and atherosclerosis. Interestingly, LPS from different types of bacteria have distinct effects on gut-barrier function, adipose inflammation, intestinal glucose absorption, blood glucose, insulin and incretins, indicating that the net effect of metabolic

**Figure 4** Colonocytes and endocrine cells express a variety of receptors able to sense and transmit signals from the microbiota environment. Microbial/pathogen-associated molecular patterns (PAMPs), lipopolysaccharides (LPS) from the microbiota are detected by pattern recognition receptors, including toll-like receptors (TLRs). Amuc_1100 is a protein expressed on the outer membrane of Akkermansia muciniphila and which has been shown to signal through TLR2 to improve gut barrier function and reduce inflammation. Metabolites secreted by certain microbes (eg, endocannabinoids (eCBs)), generated by microbial digestion of dietary components (eg, short chain fatty acids (SCFAs)) or by transformation of host-derived factors (eg, eCBs and bile acids) can be sensed through various receptors and pathways to alter intestinal integrity and host health. CB1, CB2, cannabinoid receptor type 1 and type 2; TRPV1, transient receptor potential cation channel subfamily V member 1; FXR, farnesoid X receptor; AhR, aryl hydrocarbon receptor; GPR119, GPR43, GPR41, G-protein coupled receptor 119, 43 and 41; MYD88, myeloid differentiation primary response 88; PPARγ, peroxisome proliferator-activated receptors alpha and gamma; TGR5, Takeda G protein-coupled receptor 5.
Recent advances in basic science

endotoxaemia levels on host metabolism can vary in function of gut microbiota composition.103

Disruption of PRRs expression has been associated with alterations in the microbiota composition that favour inflammation. For example, mice deficient in TLR5, which is activated by bacterial flagellin, develop colitis or metabolic syndrome, associated with an altered microbiota.104 105

The TLR activation of downstream signalling pathways has been shown to be dependent on myeloid differentiation factor 88 protein (MyD88) (figure 4). MyD88 is an essential adaptor protein for all TLRs, except TLR3106 and deletion of MyD88 in the intestines partially protects against diet-induced obesity, diabetes and inflammation and increases anti-inflammatory endocannabinoids (eCBs), restores antimicrobial peptides production and increases intestinal regulatory T cells during diet-induced obesity.107

Although many questions remain to be answered before we have a full understanding of how PAMS/DAMPs, PRRs, the microbiome and disease state interact, our growing understanding of this complex interplay is opening new therapeutic possibilities for inflammation-dependent disorders.

Bioactive lipids

Endocannabinoid system

Over the last two decades, the eCB system has been widely explored because of its extensive range of physiological effects. Among its pleiotropic effects, the eCB signalling system appears to play a key role in regulating energy, glucose and lipid metabolism but also in immunity, inflammation and more recently in microbiota-host interactions.108109

Historically, it was in 1988 that the first endogenous cannabinoid receptor type 1 (CB1) was identified as being activated by the psychoactive compound of Cannabis sativa, Δ9-tetrahydrocannabinol,110 followed by the discovery of a second receptor in 1993, the cannabinoid receptor type 2 (CB2).111 Both receptors are GPRs and share common signalling mechanisms.112 The first endogenous agonist identified was anandamide (N-arachidonoylthanolamide (AEA)). AEA is one of the key members of a large group of bioactive lipids that belong to the N-acylthanolamine (NAE) family.113 The second key ligand identified was 2-arachidonoylglycerol (2-AG).114 Since the discovery of these two major compounds, the eCB family has been expanded and is no longer restricted to only eCBs with specific activity on CB1 and CB2 receptors. For example, some eCBs also interact with PPARα and PPARγ, as well as with other membrane receptors such as GPR55, or transient receptor potential vanilloid type-1 (TRPV1) (figure 4). Besides the so-called ‘true’ eCBs, that is, eCBs able to bind CB1 and CB2, several other compounds with structural resemblance to the prototypical eCBs have been shown to interfere with the eCB response without directly activating CB1 or CB2 eCB receptors. All these molecules are referred to as eCB-like compounds or congeners and are bioactive lipids including other NAEs or members of the acylglycerol family.115 116 However, eCB-like compounds can also exert pharmacological activity of their own. For example, N-oleoylthanolamine (OEA) or N-palmitoylthanolamine (PEA) can activate PPARα and TRPV1, and OEA, N-linoleoylthanolamine (LEA) and 2-oleoylglycerol (2-OG) are able to activate GPR119.117

More recently, it was shown that both 1-palmitoylglycerol (1-PG) and 2-palmitoylglycerol (2-PG) are PPARα agonists (figure 4).118

In 2010, it was discovered that among the metabolic systems involved in the regulation of the gut barrier function the eCB system was playing a major role.108 It began with the finding that the intestinal eCB system is altered during obesity and diabetes, with an increased abundance of AEA that triggers gut permeability via CB2-dependent mechanisms.109 Interestingly, this modification of the eCB system tone was associated with changes in the gut microbiota. Moreover, pharmacological activation of the eCB system with a potent eCB agonist increased adipogenesis and disrupted the gut barrier.119 In a series of independent studies, the link between gut microbiota, adipose tissue metabolism and the eCB system has been confirmed since both genetically obese and diabetic mice (ob/ob and db/db) present a profound shift in their gut microbiota composition, which is associated with altered whole body tissue metabolism and eCB system tone.120 121 Taken together, these data strongly support a link between specific bioactive lipids, belonging to the eCB system, and the gut microbiota, the development of the adipose tissue and intestinal function.

To further explore the underlying mechanisms and to demonstrate whether the synthesis of these NAEs could be involved in the onset of metabolic disorders and changes in the gut microbiota, several mouse models have been generated in which N-acylethanolamine-hydrolyzing-specific phospholipase D (NAPE-PLD), a key synthesis enzyme, has been inactivated in either adipocytes, intestinal epithelial cells or hepatocytes.122–125

Mice lacking NAPE-PLD in adipocytes spontaneously developed obesity, insulin resistance and inflammation on a normal caloric diet and were more sensitive to high-fat diet-induced metabolic disorders.122 The adipocyte-specific deletion of NAPE-PLD decreased the thermogenic programme (ie, browning/beiging) in adipose tissue and resulted in a profound shift in the gut microbiota composition. Moreover, transferring the microbiota from adipose tissue NAPE-PLD deleted mice to germ-free recipient mice replicated the overall phenotype,122 suggesting a causal role of the gut microbiota. When deleting NAPE-PLD in intestinal epithelial cells, a different phenotype occurred. Mice became hyperphagic on first exposure to a high-fat diet and then developed exacerbated diet-induced obesity and hepatic steatosis. Mechanistically, this was attributed to a defect in the gut-to-brain axis, as hypothalamic Pomc neurons alterations were found, likely explained by changes in both intestinal and plasma eCBs. Strikingly, the gut microbiota was also affected in this model and modulating the microbiota could partially revert the phenotype.123 In the last model, mice deleted for the NAPE-PLD in the hepatocyte developed a high-fat diet-like phenotype under normal diet (ie, increased fat mass gain, hepatic steatosis, liver inflammation). These effects were related to changes in other key bioactive lipids known to be influenced by the gut microbiota such as BAs.124 Collectively, all these data and animal models suggest that the eCB system, through the NAPE-PLD, is dialoguing with the gut microbiota via the production of bioactive lipids, and it turn any dysregulation of this enzyme can lead to metabolic complications.

To further explore the potential links between the gut microbiota and the regulation of the eCB system, the endocannabinoidome (eCBome) of germ-free mice was compared with that of conventionalised mice at different time-points. The eCBome is an extension of the eCB system that comprises over 50 receptors and metabolic enzymes, and >20 lipid mediators with important functions.126 An age-dependent modification in intestinal eCBome expression and lipid mediator levels was found. Strikingly, faecal material transplantation from control mice donors to age-matched germ-free mice reversed several of these alterations, already after only 1 week.126 Altogether, this set of studies demonstrate that the gut microbiota is directly impacting the host eCBome.
In conclusion, all evidence points towards a bidirectional cross-talk between the host’s eCB system and the gut microbiota. However, further investigations are warranted to untangle the many remaining mysteries of this relationship. Adding to the complexity, it has recently been shown that the gut microbiota itself is able to produce specific eCBs. This opens new exciting opportunities of exploring the microbiota to host interaction and offers several novel putative targets for therapy.

Bile acids

Primary BAs, such as cholic acid (CA) and chenodeoxycholic acid (CDCA) in humans (and muricholic acid (MCA) in rodents), are amphipathic molecules synthesised in the liver from cholesterol. They can be conjugated to glycine or taurine prior to their secretion into bile and storage in the gallbladder. When food is ingested, BAs are released into the small intestine where they assist in the digestion and absorption of dietary fat. Around 95% of intestinal BAs are reabsorbed in the ileum to return to the liver for re-secretion. This enterohepatic circulation of BAs occurs several times a day and is an important physiological mechanism for maintaining whole body glucose, lipid and energy homeostasis to prevent hyperglycaemia, dyslipidaemia and obesity, and it protects against inflammatory metabolic diseases of the digestive and cardiovascular systems. Only a small fraction of the BAs will escape this highly efficient loop and reach the colon. These BAs are then either reabsorbed passively into the circulation or excreted via the faeces. The losses in BAs are compensated by de novo hepatic synthesis, which is regulated by fibroblast growth factor-19 (FGF19) in humans signalling in the small intestine (FGF15 in rodents).

Although the primary function of BAs is to regulate the digestion and absorption of cholesterol, triglycerides and fat-soluble vitamins, it has been recently recognised that BAs also serve an endocrine function as they act as signalling molecules. Moreover, BAs have been shown to modulate epithelial cell proliferation, gene expression, lipid, glucose and energy metabolism by activating several receptors. These receptors are the vitamin D receptor,100 pregnane X receptor,101 constitutive androstane receptor,102 farnesoid X receptor and G-protein-coupled bile acid receptor-1 (also known as Takeda G protein-coupled receptor 5 (TGR5)) (figure 4). These receptors are present in numerous tissues including the liver, intestine, muscle, brown adipose tissue and central and peripheral nervous systems and mediate the signalling cascade and activate expression of genes involved in the metabolism of BA, lipids and carbohydrates and in energy expenditure and inflammation. Signalling through FXR and TGR5 receptors has also been linked to the secretion of GI hormones such as PYY and GLP-1 (figures 3 and 4), known to be integral to the maintenance of energy and metabolic homeostasis. The role of BAs in the control of glucose, lipid and energy metabolism has been reviewed previously128 133 134 and will therefore not be reviewed in detail here.

Primary BAs are susceptible to be modified by gut microbes all along the intestinal tract. These modifications include deconjugation (the removal of amino acid residues) via bile salt hydrolase (BSH) activity and further metabolism via removal of hydroxyl groups (dehydroxylation), oxidation (dehydrogenation) or epimerisation.135 136 This results in the formation of secondary BAs such as deoxycholic acid, lithocholic acid and ursodeoxycholic acid (a secondary BA in humans, although a primary BA in rodents). This bacterial metabolism changes the bioavailability and bioactivities of BAs, and consequently their impact on the metabolic responses they are involved in. Because of their signalling capacities and the fact that BAs are chemically transformed by the gut microbiota, BAs can therefore be considered as microbiota-derived signalling metabolites. Interestingly, there is a spatio-temporal pattern to be recognised as BAs are released after food intake and then encounter different microbial communities along the intestinal tract. While BSH activity can be carried out by a wide variety of bacteria distributed among many phylogenetically different bacterial divisions, including species able to colonise the small intestine,138 the other reactions are thought to be more restricted to more specialised bacterial species that reside in the distal part of the gut. Therefore, to fully understand the role of the gut microbiota on host metabolism, it is essential to study the involvement of the different bacteria capable of converting BAs. A recent study in centenarians suggested that their specific gut microbiota signatures may partially account for their decreased susceptibility to ageing-associated illnesses, chronic inflammation and infectious diseases by generating unique secondary BAs. This implies that manipulating the BA pool via modulation of the gut microbiota composition could represent a feasible way to combat diseases.119

Aryl hydrocarbon receptor: a link to energy metabolism, inflammation and gut microbiome

The aryl hydrocarbon receptor (AhR) is expressed ubiquitously in vertebrate cells and this transcription factor is activated after ligand binding. Numerous AhR ligands exist including environmental triggers, nutrition-derived signals, various phytochemicals and bacterial metabolites such as tryptophan (figure 2). AhR ligand binding results in translocation of the AhR into the nucleus where it is bound to its dimerisation molecule AhR nuclear translocator resulting in the transcription of numerous genes involved in immunity and inflammatory processes (figure 3). Bacterial products and metabolites play a key role as activators and therefore several reports from the past years have tried to figure out the interplay of AhR with the gut microbiota (figures 3 and 4). Importantly, this AhR pathway has also been linked to energy metabolism and metabolic syndrome as there exists a reduced capacity both in preclinical and clinical settings of metabolising tryptophan into AhR binding derivatives in metabolic syndrome.141 These authors showed that an increase of AhR ligands achieved by the administration of a Lactobacillus strain improved metabolic functions paralleled by ameliorated intestinal barrier and reduced hepatic steatosis. Indigo, a naturally occurring AhR ligand with potent anti-inflammatory activities, protects against high-fat diet-induced obesity and metabolic disturbances by upregulation of Lactobacillus spp and the key barrier cytokines interleukin (IL)-10 and IL-22. Microbial tryptophan metabolites such as indole-3-ethanol, indole-3-pyruvate and indole-3-aldehyde protect the gut epithelial barrier by affecting the integrity of the apical junctional complex including myosin IIA and ezrin.143 In experimental alcoholic liver disease, a disease where the gut microbiome is substantially impaired,144 induction of AhR ligands and administration of 6-formylindolo (3,2-b) carbazole (Ficz) improved alcoholic liver disease.145 Caspase recruitment domain family member 9 mice are more susceptible to colitis and their microbiota fail to metabolise tryptophan to its respective metabolites.146 Transfer of this microbiota into wild-type mice increases colitis and can be improved by treatment with Lactobacillus strains delivering high amounts of AhR ligands. The AhR pathway might have also major implications for other inflammatory GI disorders such as coeliac disease. Patients with active coeliac disease show reduced AhR ligand production in their gut

References

1 de Vos WM, et al. Gut 2022;0:1–13. doi:10.1136/gutjnl-2021-326789.
compared with non-coeliac control subjects and furthermore in non-obese diabetic mice expressing DQ8 (a transgenic mouse that carry only human MHC class II DQ8), a high-tryptophan diet, treatment with Limosilactobacillus reuteri, a bacterial strain producing large amounts of AhR ligands or treatment with the AhR ligand Fice decreased intestinal pathologies after gluten exposure. Germ-free mice show an impaired differentiation and repair of the epidermal barrier and mice lacking AhR in keratinocytes specifically are highly susceptible to cutaneous infections and barrier damage and colonisation with a defined group of bacteria restored the barrier. It remains to be established in this model which role intestinal bacteria might play in a putative gut-skin axis. The AhR pathway therefore reflects a prototypic pathway at the interface microbiota-epithelial barrier-metabolism and immune functions.

Key bacteria and their specific molecules

Most signalling metabolites can be produced by large numbers of different gut bacteria, and hence have limited specificity. However, various bacteria can make specific molecules that have unique interactions with the host (figures 2–4). For obvious reasons, these have been very well characterised in pathogens that can make specific toxins, synthesise polysaccharides to evade the immune system or induce the host to synthesise receptors, allowing them to invade. However, recent research has identified new and unique host signalling molecules that are found in potentially symbiotic gut bacteria. These include immunomodulatory polysaccharides and spingolipids produced by Bacteroides spp and muropeptides formed by Enterococcus spp. A special class of unique molecules formed are proteins that are genetically encoded by one or a few strains of the same species. Some have been studied in detail and often involve stable or post-translationally modified proteins that have the potential to interact with host receptors as they are secreted, or cell envelope located. Some of these derived from bacteria that are already widely marketed as probiotics, including L. acidophilus NCFM that produces a large, likely glycosylated surface layer protein signalling to the DC-SIGN receptor. The 90 kDa pilus protein Spac of L. rhamnosus GG that is a partly glycosylated mucus-binding protein with unusual signalling capacity to DC-SIGN receptor on dendritic cells and the pilus-located Tad protein found in some Bifidobacterium spp that promotes colonic persistence and epithelial proliferation. A recently studied protein is the caseinolytic protease B (ClpB) of E. coli that is an antigen-mimetic of alpha-melanocyte-stimulating hormone and increases satiety via increased plasma GLP-1 and PYY production. ClpB proteins are well-known moonlighting proteins found to be partially secreted by a variety of bacteria, including Lactobacilli and Bifidobacteria. The specificity of ClpB, however, may be not so high as a ClpB-producing Hafnia alvei was also found to suppress satiety to some extent in a human trial.

Considering the effectiveness of live and pasteurised A. muciniphila administration in a proof-of-principle human trial, it is not surprising that several proteins from A. muciniphila have recently been identified with potential signalling capacity. A recent one is an 84 kDa protein (encoded by the Amuc_1381 gene) termed P9, which after oral administration was found to induce serum GLP-1 in mice. In vitro studies indicated that P9 interacts with the intercellular adhesion molecule 2 receptor. Another recently discovered protein identified is the A. muciniphila 50 kDa Amuc_1434* protein that was found to suppress LS174T cell viability via tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis pathway. However, both of these proteins are found in many bacteria other than A. muciniphila, both are annotated as proteases suggesting enzymatic activity, and both have not been localised outside the cells, not excluding the possibility that cell lysis is needed for their activity. Even more importantly, their stability has not been addressed, which is of interest as pasteurised A. muciniphila cells were as effective or even more than live cells both in human and mice models. All these arguments do not apply to the other A. muciniphila protein that was discovered to be signalling to TLR2 (figure 4). This is the 30 kDa Amuc_1100 protein that has been defined as an outer membrane protein with virtually no homology to other bacteria outside the Verrucomicrobia and in fact is suggested to be a pilus-associated protein. Further studies showed Amuc_1100 to be thermostable and preventing diet-induced obesity in a mouse model. When comparing all three proteins for their absolute abundance, it is evident that Amuc_1100 is much more abundant than the other two signalling candidates in proteomes of A. muciniphila grown on mucin. Hence, future comparative studies should determine which proteins or combinations thereof can explain the observed activity of A. muciniphila in humans.

Newly identified molecules, impact on health and their targets

Besides the classical molecules such as SCFAs, BAs or PAMPs and gut peptides (ie, GLP-1, PYY), all described as regulators of the host metabolism, gut barrier and inflammation, the role of a novel class of molecules called ‘enterosynes’ is emerging. The concept of enterosynes has been recently introduced and defined as ‘molecules originating from the gut which have the capacity to modulate duodenal contraction by targeting the enteric nervous system (ENS). Enterosynes can be chemically diverse and related to hormones, bioactive peptides/lipids, nutrients, microbiota and immune factors’. The origin of this concept is based on the observation that subjects with T2D are characterised by a duodenal hypermotility which favours glucose absorption and contributes to hyperglycaemia. It has been demonstrated that duodenal contractions are sensed by the hypothalamus and that during diabetes the duodenal hypermotility creates aberrant afferent nervous messages to the brain. Conversely, restoring natural duodenal contraction by acting on ENS neurons restores the gut-brain axis and improves insulin sensitivity.

The connections between gut microbiome, brain function and glucose metabolism are becoming a hot topic in this area of research and the role of the ENS emerged as a new target to tackle diseases such as diabetes. Although various papers are discussing strategies to modulate the gut microbiome, such as probiotics, prebiotics and faecal transplants, in view of alleviating features of metabolic syndrome, few, if not none, of them are characterising intestinal actors such as enterosynes. In search of novel gut molecules and receptors involved in glucose metabolism, the action of specific fibres known to change the gut microbiota and improve diabetes was explored. The administration of oligofructose decreased duodenal contraction frequency by controlling enteric neurons activity. This led to reduced hyperglycaemia and decreased inflammatory markers in the adipose tissue of the diabetic mice. By using lipidomic analysis, it was discovered that this oligofructose feeding selectively increased the abundance of an intestinal bioactive lipid (12-hydroxyeicosatetraenoic acid (12-HETE)) in the colonic...
cells. Strikingly, the administration of 12-HETE to diabetic mice improved glucose metabolism. The effect of 12-HETE was also confirmed ex vivo. Furthermore, they discovered that the molecular mechanism by which this bioactive lipid acts on duodenal contractility is dependent on the presence of the mu-opioid receptors (MOR) (activated by enkephalin) and PPARγ. The preclinical findings were supported by human data showing a reduction in the levels of 12-HETE and a decreased expression of the proenkephalin and MOR in the duodenum of patients with diabetes as compared with healthy subjects.170

Using various approaches with dietary supplements to tackle IBDs, new bioactive lipids with anti-inflammatory properties were identified.171 Exploiting mass spectrometry of the *E. coli* Nissle 1917 (EcN), a well-studied strain marketed as a probiotic for the treatment of colitis, led to the discovery that the concentration of 3-hydroxyoctadecenoic acid (C18-3OH) was increased. They found that oral administration of C18-3OH decreased colitis. To determine whether other bacteria present in the gut microbiota produce C18-3OH, the gut microbiota was modulated by using oligofructose. The authors found that the anti-inflammatory properties of oligofructose were associated with an increase in colonic C18-3OH concentration. Finally, they identified specific bacteria producing this bioactive lipid and discovered that C18-3OH acts by activating PPARγ.172

Altogether, these two examples show that the gut microbiota is the source of putative numerous bioactive compounds (figure 2) acting on host receptors involved in the regulation of metabolism and inflammation (figure 3).

Whereas some metabolites are desired for health, others may be harmful, but evidence only derives from association studies or animal testing. Three metabolites with negative impact have been subject to recent studies, including fructoselysine, an advanced glycation end product (AGE), trimethylamine N-oxide (TMAO) and imidazole propionate (IMP).

AGEs are Maillard reaction products formed in our foods by thermal processing when free amino groups of proteins and amino acids react with reducing carbohydrates, forming compounds that are poorly bioavailable. A body of mechanistic evidence has linked AGEs to T2D and CRC through stimulation of the pro-inflammatory response via the activation of the receptor of AGEs,173 174 an increase in gut permeability—allowing closer interaction of AGEs with colonic epithelium—and consequential leakage of bacterial toxins into the systemic circulation.175 Fructoselysine is an Amadori product formed from lysine and glucose that is one of the primary dietary AGEs. Earlier studies showed that *E. coli* has the capacity to respire fructoselysine.176 However, recent analysis showed that it can be converted into butyrate by members of the genus *Intestimonas* spp via a novel pathway.177 Of note, the capability to degrade fructoselysine was experimentally and computationally only observed in formula-fed but not in breast-fed infants, which may relate to high contents of this compound in formulas after thermal treatment.178 Further studies should address the causality of fructoselysine and other AGEs in T2D and other diseases and the involvement of intestinal bacteria in their conversion. A recent study also described the complete utilisation of N-ε-carboxymethyllysine, another major AGE, by *Cloacibacillus* and potentially *Oslobacter* spp.179

TMAO is related to the intake of quaternary amines, such as betaine, choline and L-carnitine, which are commonly found in vegetables, fruits, meat and seafood and are well-known bacterial osmoprotectants.179 180 Several gut bacteria including several Proteobacteria can convert these quaternary ammonium ions via TMA lyase and its activating enzyme (CutCD) into acetaldehyde and trimethylamine (TMA). TMA then can enter the bloodstream and is converted by flavin monoxygenase in the liver to TMAO. Recent studies have shown that TMAO in serum is strongly associated with atherosclerosis and cardiovascular risks.171 In addition, TMAO has been shown to promote formation of atherosclerotic plaques in a mouse model.182 Moreover, TMAO is a common ureaemic toxin.183 Hence, there is considerable interest in understanding the metabolism of these quaternary ammonium ions into compounds that do not lead to TMA or other TMAO precursors. New insight has come from the biochemical and pathway analysis of *Eubacterium limosum* and its related gut isolate *E. malossoirans* that were found to deaminate betaine and other quaternary amines in a novel process involving bacterial cell compartments and leading to the production of acetate and butyrate.184–186 While the latter bacteria are highly related and appear to have a unique vitamin B12-dependent metabolic pathway, this does not hold for the metabolism of histidine that may lead to the production of IMP. It has been shown that concentration of IMP was increased in the serum of patients with T2D.187 It was recently found that IMP is produced from histidine by intestinal bacteria that impaired insulin signalling and glucose tolerance through the mammalian target of rapamycin complex 1-dependent pathway.188 Two unrelated bacteria, *Streptococcus mutans* and *Eggerthella lenta* have been identified as IMP producers, confirming the fact that many metabolites are produced by several groups of intestinal bacteria that may not share any phylogenetic relations. Altogether, these examples indicate the involvement of intestinal bacteria in generating undesired compounds but identified also new anaerobes that may detoxify these and even convert these in products such as butyrate that have beneficial signalling potential (figures 2 and 3).

**GENERAL CONCLUSION AND PERSPECTIVES**

Over the last two decades, considerable progress has been achieved. From initial clinical observations to more mechanistic approaches, the field of gut microbiota and health is evolving to irresistible causal links. However, there are still numerous studies that claim causality when in fact only correlations are being demonstrated. Moving from correlation to causality remains an important and required step to better design putative interventions based on the modulation of the gut microbiota or by using specific active compounds.175 189 Thanks to the numerous efforts and the advance in omics analysis, the scientific community is gradually moving towards personalised medicine and the microbiome era is clearly an important part of the paradigm shift in the future of medicine and nutritional approaches.

**Contributors** PDC has prepared a proposal on the conception of the overall content of the manuscript. PDC, HT, WMDv and MVH have revised, amended and approved the proposal. PDC, HT, WMDv and MVH have collected content, selected the key references, written and critically reviewed the content of the manuscript. PDC and MVH have prepared the figures. PDC, HT, WMDv and MVH have all revised the final version of the manuscript. PDC, HT, WMDv and MVH contributed equally to this paper.

**Funding** PDC is research director at FRS-FNRS (Fonds de la Recherche Scientifique) and the recipient of grants from FNRS (Projet de Recherche PDR-convention: FNRS T.0030.21, CDR-convention: J.0027.22, FRFS-WELBio: WELBio-CR-2017C-02E, WELBio-CR-2019C-02R, EOS: program no. 30770923 and EOS program no. 40007505). WMDv was supported by the SIAM Grant (202.002.002) of the Netherlands Organization for Scientific Research. HT is supported by the excellence initiative VASCage (Centre for Promoting Vascular Health in the Ageing Community), an R&D K-Centre (COMET program—Competence Centers for Excellent Technologies) funded by the Austrian Ministry for Transport, Innovation and
Recent advances in basic science

Technology, the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg and Vienna.

Competing interests PDC and WMdV are inventors on patent applications dealing with the use of Akkermansia muciniphila and its components in the treatment of metabolic disorders. PDC and WMdV are co-founders of A-Mansia Biotech. PDC is co-founder of Enterosys. WMdV is co-founder of Caels Health and inventor on patents on the use of Eubacterium hallii.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of changes was made. See: https://creativecommons.org/licenses/by/4.0/.

This is an open access article distributed in accordance with the ethics approval.

Ethics approval

Inventor on patents on the use of

2019;8:E396–400.

2021;19:55–71.

2012;6:1415–26.

2010;12:3213–27.

2008;9:374.

2021;33:1098–110.

2020;32:834–41.

2013;368:407–15.

2014;32:834–41.

2012;143:913–6.

2021;70:92–105.

2021;70:2297–306.

2018;68:3741–6.

2018;67:1716–25.

2021;9:1302.

2021;9:214.

2020;6:16.

2021;9:954–64.

2020;9:1302.

2021;9:954–64.

2018;6:16.

2020;32:323218.

2018;9:569:655–62.

2019;57:1605–15.

2010;106:2371–6.

2011;108 Suppl 1:4562–9.

2021;70:2297–306.

2012;26:611–9.

2019;464:59–65.

2010;10:2371–6.

2008;57:1605–15.

2019;32:834–41.

2013;36:407–15.

2012;143:913–6.

2021;70:2297–306.

2021;70:92–105.

2021;7:259–60.

2018;68:3741–6.

2018;33:1137–40.

2021;70:92–105.

2021;70:2297–306.

2021;70:2297–306.

2021;70:92–105.

2021;70:2297–306.

2021;7:259–60.

2021;7:259–60.

2021;7:259–60.

2021;7:259–60.

2021;7:259–60.

de Vos WM, et al. Gut 2022;0:1–13. doi:10.1136/gutjnl-2021-326789 on 1 February 2022. Downloaded from http://gut.bmj.com/ Gut: first published as 10.1136/gutjnl-2021-326789 on 1 February 2022. Published by guest. Protected by copyright.
51 Cani PD, Van Hul M. Mediterranean diet, gut microbiota and health: when age and calories do not add up! *Gut* 2020;69:1167–8.
52 Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. *Nat Rev Gastroenterol Hepatol* 2018;15:671–82.
53 Louis P, Flint H. Formation of propionate and butyrate by the human colonic microbiota. *Environ Microbiol* 2017;19:29–41.
54 Chambers ES, Preston T, Frost G, et al. Role of gut Microbiota-Generated short-chain fatty acids in metabolic and cardiovascular health. *Curr Nutr Rep* 2018;7:198–206.
55 Frost G, Sleeth ML, Sahni-Arisoyu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nat Commun* 2014;5:3611.
56 Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol* 2015;11:577–91.
57 Rastelli M, Cani PD, Kraus N. The gut microbiota influences host endocrine functions. *Endocr Rev* 2019;40:1271–84.
58 Daubioul CA, Taper HS, De Wispelaere I, et al. Dietary oligofructose lessens hepatic steatosis, but does not prevent hyperglycemia in obese Zucker rats. *J Nutr* 2000;130:1314–9.
59 Cani PD, Deevere C, Delzenne NM. Insulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like-peptide-1 and ghrelin) in rats. *Br J Nutr* 2004;92:512–6.
60 Cani PD, Neyrinck AM, Maton N, et al. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. *Obes Res* 2003;15:1000–7.
61 Cani PD, Kraus C, Ilesgias MA, et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. *Diabetes* 2005;54:1848–50.
62 Delzenne NM, Cani PD, Daubioul C, et al. Impact of inulin and oligofructose on gastrointestinal peptides. *Br J Nutr* 2005;93 Suppl 1:1517–61.
63 Cani PD, Hoste S, Guiot Y, et al. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. *Br J Nutr* 2007;98:35–72.
64 Everard A, Lazarvec V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. *Diabetes* 2011;60:2775–86.
65 Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota composition during obesity in mice through a mechanism involving GLP-1 driven improvement of gut permeability. *Cell Metab* 2011;6:1091–1103.
66 Wang X, Gibson GR. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. *Appl Environ Microbiol* 1993;59:273–80.
67 Aziz AA, Kenney LS, Goulet B, et al. The orphan G protein-coupled receptor for cannabinoids. *Nature* 2001;410:148–52.
68 Liu Y, Zou M, Hua Y, et al. Production of butyrate from lysine and the Amadori rearrangement product, α-ketoglutarate, by commensal Anaerostipes hallii. *Appl Environ Microbiol* 2010;76:237–41.
69 Kimur a Y, Byndloss MX, Tsolis RM, et al. Variation in microbial composition of the canine gut with age and body weight. *Gut Microbes* 2011;2:307–18.
70 Rehoo BY, Wang YY, Belkaid Y, et al. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. *Obes Res* 2003;11:1486–92.
71 Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIc-1. *Nature* 2013;496:238–42.
72 Yan W, Yuan J, Li J, et al. Overweight and underweight status are linked to specific gut microbiota and intestinal tricarboxylic acid cycle intermediates. *Clin Nutr* 2020;39:389–98.
73 Bertani B, Ruiz N. Function and biogenesis of lipo polysaccharides. *Ecol Evol* 2018;8:EPS-0011-2018.
74 Walsh D, McCarthy J, D’riscoll C, et al. Pattern recognition receptors–molecular orchestrators of inflammation in inflammatory bowel disease. *Cytokine Growth Factor Rev* 2013;24:91–104.
75 Quenselva V, Nicolle DM, Torres D, et al. Toll-like receptor 2 (TLR2)-dependent–positive and TLR4-independent–negative regulation of proinflammatory cytokines by mycobacterial lipopamans. *J Immunol* 2004;172:4245–32.
76 Poltorak A, He X, Smirnova I, et al. Defective LPS signalling in CHIHe/l and C57Bl10ScCr mice: mutations in TLR4 gene. *Science* 1998;282:2085–8.
77 Belkaid Y, Harrison OJ. Homeostatic immune and the microbiota. *Immunity* 2017;46:562–76.
78 Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. *Cell* 2010;140:1044–66.
79 Cani PD, Amar J, Ilesgias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 2007;56:1761–72.
80 Régnier M, Van Hul M, Kraus C, et al. Gut microbiome, endotoxin control of gut barrier function and metabolic diseases. *J Endocrinol* 2021:248:R67–82.
81 Tilg H, Burcelin R, Temarori L. Liver tissue microbiome in NAFLD: next step in understanding the gut–liver axis? *J Hepatol* 2020;72:1373–4.
82 Anthé FF, Barra NG, Cavallari JF, et al. Metabolic endotoxemia is dictated by the type of lipopolysaccharide. *Cell Rep* 2021;36:109691.
83 Vijay-Kumar M, Atiken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. *Science* 2010;328:228–31.
84 Vijay-Kumar M, Sanders CJ, Taylor RT, et al. Deletion of TLR5 results in spontaneous insulin resistance. *Diabetes* 2017;66:1373–4.
85 Takeda K, Akira S. Microbial recognition by Toll-like receptors. *J Dermatol Sci* 2004;34:73–82.
86 Everard A, Geurts L, Caeser R, et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. *Nat Commun* 2014;5:5648.
87 Muccillo GG, Naslan D, Bäckhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. *Mol Syst Biol* 2010;6:392.
88 Cani PD, Ploover H, Van Hul M, et al. Endocannabinoids—its role in the gut microbiota and host metabolism. *Nat Rev Endocrinol* 2016;12:133–43.
89 Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 1988;34:605–13.
90 Munro S, Thomas KL, Abu-Shaab M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 1993;365:61–5.
91 Howlett AC, Barth F, Bonner TI, et al. InternationalUnion of pharmacology. XVIII. classification of cannabinoid receptors. *Pharmacol Rev* 2002;54:161–202.
92 Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 1992;258:1946–9.
93 Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoacylglycerol, present in rat gut, that binds to cannabinoid receptors. *Biochem pharmacol* 1995;50:83–90.
94 Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded cannabinoid system in neurological disorders. *Nat Rev Neurol* 2020;16:9–29.
Recent advances in basic science

116 Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018;17:623–39.

117 Syed SK, Bui HH, Beavers LS, et al. Regulation of GPR119 receptor activity with endocannabinoid-like ligands. Am J Physiol Endocrinol Metab 2012;303:E1469–78.

118 Depommier C, Vitale RM, Lannotti FA, et al. Beneficial effects of Akkermansia muciniphila are not associated with major changes in the circulating Endocannabinoidome but linked to higher Mono-Palmito-Lyso-Glycerol levels as new PPARα agonists. Cells 2021;10:185.

119 Geurts L, Muccioli GG, Delzenne NM, et al. Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxemia. PLoS One 2013;8:e55563.

120 Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2012;1:149.

121 Suriano F, Manca C, Flamand N, et al. Exploring the endocannabinoidome in genetically obese (db/db) and diabetic (db/db) mice: links with inflammation and gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159056.

122 Geurts L, Everard A, Van Hul M, et al. Adipose tissue NAE-PFLD controls fat mass development by altering the browsing process and gut microbiota. Nat Commun 2015;6:495.

123 Everard A, Piovera H, Rastelli M, et al. Intestinal epithelial N-acetylglucosamidase regulates dietary fat to metabolic adaptations in obesity and steatosis. Nat Commun 2019;10:457.

124 Lefort C, Roumain M, Van Hul M, et al. Hepatic NAE-PFLD is a key regulator of liver lipid metabolism. J Lipid Res 2020;61:91247.

125 Rastelli M, Van Hul M, Terrai R, et al. Intestinal NAE-PFLD contributes to short-term regulation of food intake via gut-to-brain axis. Am J Physiol Endocrinol Metab 2020;3:2019:E647–47.

126 Manca C, Boubertakh E, Leblanc N, et al. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signalling. J Lipid Res 2020;61:60–75.

127 Cohen LJ, Estherday D, Kim S-H, et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 2017;549:48–53.

128 Lefort C, Cani PD. The liver under the spotlight: bile acids and oxysterols as pivotal actors controlling metabolism. Cells 2021;10:4000.

129 Chiang YJL, Ferrell JD. Bile acids as metabolic regulators and nutrient sensors. Annu Rev Nutr 2019;39:297–319.

130 Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313–6.

131 Inunah CA, Jiang M, Xie W. Nuclear receptor FXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 2011;1812:956–63.

132 Wagner M, Hallassius E, Marschall H-J, et al. The bile acids in bile: functional and comparative metagenomic analysis of dietary fat to metabolic adaptations. Cell Metab 2020;32:406–20.

133 Kuipers F, Bloks VN, Groen AK. Beyond intestinal soap--bile acids in metabolic regulation of food intake and energy balance. Gut Microbes 2017;8:1–13. doi:10.1080/21623010.2016.1247055.

134 Lamas B, Hernandez-Galan L, Galipeau HJ, et al. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Sci Transl Med 2020;12:eaba6024.

135 Uberoi A, Bartow-McKenney C, Zheng Q, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe 2020;27:292–302.

136 Erturk-Hadimier D, Oh SF, Okan NA, et al. Symbiota exploit complex signaling to educate the immune system. Proc Natl Acad Sci U S A 2019. doi:10.1073/pnas.1901987116. [Epub ahead of print: 06 December 2019].

137 Oh SF, Praveena T, Song H, et al. Host immunomodulatory lipids created by symbiota from dietary amino acids. Nature 2021;600:302–7.

138 Griffin ME, Espinosa J, Becker IL, et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 2021;373:1040–6.

139 Konstantinos SR, Smits H, de vos WM, et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A 2008;105:19474–9.

140 Tytgat HLP, van Teijlingen NH, Sullan RMA, et al. Probiotic gut microbiota isolates interact with dendritic cells via glycosylated heterotrimeric Gli. PLoS One 2011;6:e15184–7.

141 O’Connell Motherway M, Zomer A, Leahy SC, et al. Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (TAD) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci U S A 2011;108:11217–22.

142 O’Connell Motherway M, Houston A, O’Callaghan G, et al. A bifidobacterial pili-associated protein promotes colonial epithelial proliferation. Mol Microbiol 2019;111:287–301.

143 Breton J, Tonnene N, Lucas N, et al. Gut Commensal E. coli Proteins Activate Host Sensory Pathways following Nutrient-Induced Bacterial Growth. Cell Metab 2019;23:324–34.

144 Legrand R, Lucas N, Dominique M, et al. Commensal Hafnia alvheim strain reduces food intake and fat mass in obese mice-a new potential probiotic for appetite and body weight management. Int J Obes 2020;44:1041–51.

145 Depommier C, Everard A, Draut C, et al. Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome. Gut Microbes 2021;13:1994270.

146 Yoon HS, Cho CH, Yun MS, et al. Akkermansia muciniphila secretes a glucagon-like peptide 1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol 2021;6:563–73.

147 Cani PD, Knauf A. A newly identified protein from Akkermansia muciniphila stimulates GLP-1 secretion. Cell Metab 2021;33:1073–5.

148 Meng X, Zhang J, Wu H, et al. Akkermansia muciniphila Aspartic Protease Amuc_1434 inhibits Human Colorectal Cancer LS174T. Cell Viability via TRAIL-Mediated Apoptosis Pathway. Int J Mol Sci 2020;21:3285.

149 Depommier C, Van Hul M, Everard A, et al. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes 2020;11:1231–45.

150 Piovera H, Everard A, Draut C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic fat mice. Nat Metab 2017;1:72–7.

151 Ottnan N, Reunanen J, Meijerink M, et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One 2012;7:e37004.

152 Ottnan N, Davids M, Suarez-Diez M, et al. Genome-SCALE Model and Omics Analysis of Metabolic Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading Lifestyle. Appl Environ Microbiol 2019;85:e01514–7.

153 Kaufn C, Abot A, Wemelle E, et al. Targeting the Enteric Nervous System to Treat Metabolic Disorders ? “Enterones” as Therapeutic Gut Factors. Neuroendocrinology 2020;110:139–46.

154 Fournel A, Drougard A, Duparc J, et al. Apeps targets gut contraction to control glucose metabolism via the brain. Gut 2017;66:258–69.

155 Kaufn C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin sensitivity to favor hepatic glycogen storage. J Clin Invest 2011;121:3554–63.

156 Abot A, Lucas M, Bautzova T, et al. Galanin enhances systemic glucose metabolism through enteric nitric oxide Synthase-expressed neurons. Mol Metab 2018;10:160–8.

157 Abot A, Wemelle E, Launerie C, et al. Identification of new enterosynes using prebiotics: roles of bioactive lipids and mu-opioid receptor signalling in humans and mice. Gut 2021;70:1087–87.

158 Abot A, Cani PD, Knauf A. Impact of intestinal peptides on the enteric nervous system: novel approaches to control glucose metabolism and food intake. Front Endocrinol 2019;10:328.

159 Pujo J, Petitfils C, Le Faouder P, et al. Bacteria-Derived long chain fatty acid exhibits anti-inflammatory properties in colitis. Gut 2021;70:1088–97.

160 Sakellaris S, Fragkou P, Levidou G, et al. Clinical significance of AGE-mucin response by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Sci Transl Med 2020;12:eaba6024.
Recent advances in basic science

174 Peppa M, Mavroeidi I. Experimental animal studies support the role of dietary advanced glycation end products in health and disease. *Nutrients* 2021;13:3467. doi:10.3390/nu13103467

175 Qu W, Yuan X, Zhao J, et al. Dietary advanced glycation end products modify gut microbial composition and partially increase colonic permeability in rats. *Mol Nutr Food Res* 2017;61:mntr.201700118:1700118.

176 Wiame E, Delperre G, Collard F, et al. Identification of a pathway for the utilization of the Amadori product fructoselysine in *Escherichia coli*. *J Biol Chem* 2002;277:42523–9.

177 Bui TPN, Troise AD, Nijsse B. Intestinimonas-like bacteria are important butyrate producers that utilize Nε-fructosyllysine and lysine in formula-fed infants and adults. *Journal of Functional Foods* 2020;70:103974.

178 Bui TPN, Troise AD, Fogliano V, et al. Anaerobic degradation of N-ε-Carboxymethyllysine, a major glycation end-product, by human intestinal bacteria. *J Agric Food Chem* 2019;67:6594–602.

179 Zeisel SH, Mar M-H, Howe JC, et al. Concentrations of choline-containing compounds and betaine in common foods. *J Nutr* 2003;133:1302–7.

180 Demarquoy J, Georges B, Rigaute C, et al. Radioisotopic determination of L-carnitine content in foods commonly eaten in Western countries. *Food Chem* 2004;86:137–42.

181 Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. *Nat Rev Microbiol* 2018;16:171–81.

182 Koay YC, Chen Y-C, Wall JA, et al. Plasma levels of trimethylamine-N-oxide can be increased with ‘healthy’ and ‘unhealthy’ diets and do not correlate with the extent of atherosclerosis but with plaque instability. *Cardiovasc Res* 2021;117:435–49.

183 Velasquez MT, Ramezani A, Manal A, et al. Trimethylamine N-oxide: the good, the bad and the unknown. *Toxins* 2016;8:326.

184 Picking JW, Behrman EJ, Zhang L, et al. MtpB, a member of the MttB superfamily from the human intestinal acetogen *Eubacterium limosum*, catalyzes proline betaine demethylation. *J Biol Chem* 2019;294:13697–707.

185 Kountz DJ, Behrman EJ, Zhang L, et al. MtcB, a member of the MttB superfamily from the human gut acetogen *Eubacterium limosum*, is a cobalamin-dependent carnitine demethylase. *J Biol Chem* 2020;295:11971–81.

186 Feng Y, Bui TPN, Stams AJM, et al. Comparative genomics and proteomics of *Eubacterium maltosivorans*: functional identification of trimethylamine methyltransferases and bacterial microcompartments in a human intestinal bacterium with a versatile lifestyle. *Environ Microbiol* 2022. doi:10.1111/1462-2920.15886. [Epub ahead of print: 02 Jan 2022].

187 Molinaro A, Bel Lassen P, Henriksson M, et al. Imidazole propionylate is increased in diabetes and associated with dietary patterns and altered microbial ecology. *Nat Commun* 2020;11:5881.

188 Koh A, Molinaro A, Ståhlman M, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. *Cell* 2018;175:947–61.

189 Van Hul M, Le Roy T, Prifti E, et al. From correlation to causality; the case of *Subdoligranulum*. *Gut Microbes* 2020;12:1–13.

190 Sender R, Fuchs S, Milo R. Are we really Vastly Outnumbered? revisiting the ratio of bacterial to host cells in humans. *Cell* 2016;164:337–40.

191 Neugent ML, Hulyalkar NV, Nguyen VH, et al. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. *mBio* 2020;11:e00219–20.